PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V3024 - Common Stock
PERSPECTIVE THERAPEUTICS INC
NYSEARCA:CATX (12/20/2024, 8:04:02 PM)
After market: 2.95 +0.1 (+3.51%)2.85
+0.01 (+0.35%)
Company Profile
Perspective Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 116 full-time employees. The company went IPO on 2002-05-31. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The company is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON
P: 12066760900
Employees: 118
CATX News
2 days ago - Market News VideoBargain Hunters Take Note: Insider Cluster-Buying At CATX26 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Participate in Upcoming Investor Conferences in DecemberSEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
a month ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of...
a month ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
a month ago - Perspective Therapeutics, Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsAdvancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated...
2 months ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Participate in Upcoming Investor Conferences in NovemberSEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
CATX Twits
Here you can normally see the latest stock twits on CATX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
